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Abstract Stimulation of neutrophils with the chemoattractant
fMet-Leu-Phe (fMLP) triggers phosphorylation/inactivation of
the K- and L-isoforms of glycogen synthase kinase 3 (GSK-3)
with phosphorylation of the K-isoform predominating. These
reactions were monitored with a phosphospecific antibody that
only recognized the K- or L-isoforms of GSK-3 when these
proteins were phosphorylated on serine residues 21 and 9,
respectively. Inhibitor studies indicated that phosphorylation of
GSK-3K may be catalyzed by the combined action of p90-RSK
and Akt and may represent a new strategy by which G protein-
coupled receptors inactivate GSK-3. Inactivation of GSK-3 may
be one of the mechanisms that delay apoptosis in fMLP-
stimulated neutrophils. ß 2001 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Resolution of in£ammation requires the recognition and
phagocytosis of apoptotic neutrophils by macrophages [1].
Apoptosis of neutrophils can be delayed by a variety of che-
moattractants (e.g. interleukin-8, fMet-Leu-Phe (fMLP)) and
other in£ammatory mediators (granulocyte/macrophage col-
ony-stimulating factor, lipopolysaccharide) through complex
mechanisms that can involve phosphoinositide 3-kinase (PI 3-
K), Akt or the extracellular signal-regulated kinase (ERK)
pathway (e.g. [2,3]). We have recently reported that the Ser/
Thr protein kinase p90-RSK-2 undergoes rapid activation in
fMLP-stimulated neutrophils [4]. Complete activation of p90-
RSK-2 requires the phosphorylation of this kinase on multiple
sites by both autophosphorylation and the action of upstream
kinases (e.g. ERK, 3-phosphoinositide-dependent protein ki-
nase 1 (PDK 1)) [5^7]. Relatively few physiological substrates
for p90-RSK-2 have been identi¢ed to date even though this
kinase may have a major role in promoting cell survival [8,9].
Glycogen synthase kinase 3 (GSK-3) is a constitutively ac-
tive protein kinase that participates in hierarchical phosphor-
ylation reactions by catalyzing the phosphorylation of Ser/Thr
residues that are located on the N-terminal side of a phospho-
serine residue (^S/TXXXS(P)^) (e.g. [10]). Transfection of ac-
tive GSK-3L into certain cells can promote spontaneous apo-
ptosis [11] or enhance apoptosis triggered by the other agents
[12]. Phosphorylation of GSK-3K on Ser-21 or GSK-3L on
Ser-9 inhibits the catalytic activity of these isoforms [10,13]
and thus may reduce their proapoptotic activity. Phosphory-
lation/inactivation of GSK-3 is catalyzed by Akt or p90-RSK
in cells treated with growth factors that bind to receptor ty-
rosine kinases (e.g. [13,14]) or by protein kinase A (PKA) in
cells stimulated with an agonist that binds to a G protein-
coupled receptor [15,16]. fMLP binds to a G protein-coupled
receptor on neutrophils (e.g. [17]) and triggers a myriad of
biochemical events that include activation of p90-RSK-2,
Akt and PKA (e.g. [4,17]). In this paper we report that neu-
trophils stimulated with fMLP exhibit rapid phosphorylation/
inactivation of GSK-3. Inhibitor studies indicated that this
reaction may be catalyzed by both p90-RSK and Akt. Thus,
G protein-coupled receptors may employ a variety of path-
ways to promote phosphorylation/inactivation of GSK-3.
2. Materials and methods
2.1. Materials
A goat polyclonal antibody raised to a peptide corresponding to
residues 722^740 of human RSK-2 (RSK-2(C-19) Ab) was obtained
from Santa Cruz Biotechnology, Santa Cruz, CA, USA. A⁄nity-pu-
ri¢ed, rabbit polyclonal phosphospeci¢c antibodies to GSK-3 (phos-
pho-GSK-3K/L(Ser-21/9) Ab), Akt (phospho-Akt(Thr-308) Ab) and
p90-RSK (phospho-p90-RSK(Ser-381) Ab) and a GSK-3 fusion pro-
tein were purchased from Cell Signaling Technology, Beverly, MA,
USA. This GSK-3 fusion protein was a ‘crosstide’ of molecular mass
30 kDa that consisted of a peptide containing the residues surround-
ing the Ser-21/9 site in GSK-3K/L chemically attached to bacterially
expressed paramyosin. Wortmannin, LY 294002 and PD 98059 were
obtained from Calbiochem, San Diego, CA, USA. Protein A-4L aga-
rose was purchased from Sigma Chemical, St. Louis, MO, USA.
Sources of all other materials are described elsewhere [4,18,19].
2.2. Preparation of neutrophils
Guinea pig peritoneal neutrophils were prepared as described pre-
viously [20].
2.3. Cell stimulation and Western blotting
These procedures are described in detail in [18] and [4,19], respec-
tively. At the end of these experiments, the blots were stripped and
stained with an antibody that recognized both the phosphorylated and
non-phosphorylated forms of Akt or ERK to con¢rm that equal
amounts of protein were present in each lane of the gel (e.g. [4]).
2.4. Immunoprecipitation and assay of p90-RSK-2
Neutrophils (1.0U108/ml) were stimulated with 1.0 WM fMLP in a
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phosphate-bu¡ered saline medium (135 mM NaCl, 2.7 mM KCl, 16.2
mM Na2HPO4, 1.47 mM KH2PO4, 0.90 mM CaCl2 and 0.50 mM
MgCl2, pH 7.35) containing 7.5 mM D-glucose. At the appropriate
time, the cells were rapidly lysed by transferring 0.50 ml of the reac-
tion mixture to a microcentrifuge tube containing 2Uconcentrated
‘immunoprecipitation bu¡er’ (ip-B) and rapidly mixed. The ¢nal com-
position of ip-B was 50 mM Tris^HCl (pH 7.5), 150 mM NaCl,
5.0 mM MgCl2, 1.0 mM EGTA, 50 mM NaF, 10 mM sodium pyro-
phosphate, 1.0% (v/v) Nonidet P-40, 2.5% (v/v) glycerol, 1.0 mM
Na3VO4 and 1.0 mM phenylmethylsulfonyl £uoride. After 30 min
at 4‡C, the lysates were centrifuged for 10 min at 1000Ug to remove
insoluble debris, the RSK-2(C-19) Ab (10 Wg/ml) was added to the
soluble fraction, and this fraction was then incubated for 2 h at 4‡C.
A 50% slurry of protein A Sepharose beads (60 Wl) was added to the
reaction mixture, which was then incubated for an additional hour at
4‡C. The resulting beads containing the bound immune complexes
were washed three times with ip-B (1.0 ml/wash) and three times
with kinase bu¡er (20 mM MgCl2, 1.0 mM sodium vanadate, 5.0
mM NaF, 20 mM L-glycerophosphate, 20 mM p-nitrophenyl-
phosphate and 50 mM HEPES, pH 7.4) [21]. The bound immune
complexes were resuspended in 25 Wl of kinase bu¡er containing
100 WM ATP and the GSK-3 fusion protein (10 Wg/ml). Follow-
ing an incubation of 30 min at 37‡C, an equal volume of 2Uconcen-
trated ‘solubilization bu¡er’ was added to the reaction mixtures
and the samples were boiled for 5.0 min. The ¢nal concentration of
sample bu¡er after mixing was 2.3% (v/v) SDS, 62.5 mM Tris^HCl
(pH 6.8), 5.0 mM EDTA, 10.0% (v/v) glycerol, 5.0% (v/v) 2-mercap-
toethanol and 0.002% (v/v) bromophenol blue. The proteins
were separated by SDS^PAGE (70 Wg/ml) on 9.0% (v/v) polyacryl-
amide slab gels and phosphorylation of the fusion protein was
monitored by Western blotting with the phospho-GSK-3K/L(Ser-
21/9) Ab.
2.5. Analysis of data
Unless otherwise noted, all of the observations from the Western
blots were con¢rmed in at least three separate experiments performed
on di¡erent preparations of cells. The numbers of observations (n) are
also based on di¡erent preparations of cells.
3. Results
3.1. Phosphorylation of GSK-3 in stimulated neutrophils
A phosphospeci¢c antibody was utilized to monitor phos-
phorylation of GSK-3 in neutrophils (Fig. 1). The phospho-
GSK-3K/L(Ser-21/9) Ab employed reacted with both the
K- and L-isoforms of this kinase only when they were phos-
phorylated on Ser-21 and Ser-9, respectively. This antibody
reacted with only two proteins in unstimulated (lane f) and
stimulated neutrophils (lane a) and these proteins exhibited
masses consistent with the K- (arrow) and L- (closed arrow-
head) isoforms of GSK-3. Stimulation of neutrophils with
1.0 WM fMLP for 6.0 min resulted in an increased reactivity
of these bands towards the phosphospeci¢c antibody with the
K-isoform usually predominating. The amounts of GSK-3L
that reacted with the antibody were variable.
Activation of the G protein-coupled L-adrenergic receptor
with adrenaline in a variety of cells leads to rapid phosphor-
ylation of the K- and L-isoforms of GSK-3 on Ser-21 and Ser-
9, respectively [15,16]. These reactions were completely
blocked by an antagonist of PKA (10 WM H89) [15]. How-
ever, a variety of antagonists of PKA (10 WM H89, 100 WM
H-7 or 100 WM HA1004) [15,22] did not block the increase in
phosphorylation of GSK-3K on Ser-21 in fMLP-stimulated
neutrophils (Fig. 1) (n = 4). Interestingly, the GSK-3L band
was partially reduced by 10 WM H89 but was largely insensi-
tive to H-7 and HA1004. Increasing the concentration of H89
to 50 WM substantially inhibited phosphorylation of both the
K- and L-isoforms of GSK-3 (Fig. 1). Recent studies have
established that H89 can inhibit several protein kinases in
addition to PKA [23].
3.2. Kinetics of phosphorylation of GSK-3, Akt and p90-RSK
in stimulated neutrophils
Phosphospeci¢c antibodies were utilized to monitor the
phosphorylation of GSK-3, Akt and p90-RSK in neutrophils
stimulated with fMLP (Fig. 2). The phosphospeci¢c antibod-
ies to Akt and p90-RSK only recognized these kinases when
they were phosphorylated on Thr-308 and Ser-381, respec-
tively. Activation of Akt requires phosphorylation at Thr-
308 [24], whereas the role of Ser-381 in the activation of
p90-RSK is complex ([6,7] ; data presented below). GSK-3
underwent phosphorylation in stimulated neutrophils with
maximal phosphorylation occurring at 3.0^6.0 min (Fig.
2A). In contrast, Akt underwent maximal phosphorylation
within 1.0 min followed by signi¢cant dephosphorylation at
3.0^6.0 min (Fig. 2B). Interestingly, neutrophils stimulated
with fMLP exhibited phosphorylation of p90-RSK with ki-
netics nearly identical to that of GSK-3 (Fig. 2C).
3.3. E¡ects of various antagonists on the phosphorylation of
GSK-3
A variety of antagonists were employed to identify the pro-
tein kinase(s) that catalyze phosphorylation of GSK-3K in
fMLP-stimulated neutrophils (Fig. 3). Wortmannin is an irre-
versible inhibitor of PI 3-K (e.g. [17]). Products of PI 3-K are
required for translocation of PDK-1 to the membrane and
activation of Akt in cells (e.g. [17]). Wortmannin (200 nM)
Fig. 1. Phosphorylation of GSK-3 in stimulated neutrophils. Neu-
trophils were stimulated with 1.0 WM fMLP for 6.0 min and phos-
phorylation of GSK-3 was monitored by Western blotting with a
phosphospeci¢c antibody which only recognized GSK-3K (arrow) or
GSK-3L (closed arrowhead) when these isoforms were phosphorylat-
ed on Ser-21 and Ser-9, respectively. Lane a is for stimulated cells.
Lane f is for unstimulated neutrophils. In certain cases (lanes b^e)
the cells were treated with inhibitors for 30 min at 37‡C and then
stimulated with 1.0 WM fMLP for 6.0 min. Lanes b^e are for stimu-
lated cells treated with: (b) 10 WM H89; (c) 50 WM H89; (d) 100
WM H-7 and (e) 100 WM HA1004. Conditions for cell stimulation
and Western blotting are referenced in Section 2.
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completely blocked phosphorylation of Akt on Thr-308 (Fig.
3B, c1 and c2) but did not a¡ect phosphorylation on GSK-3K
(Fig. 3A, c1 and c2). Compound PD 98059 blocks activation
of p90-RSK in neutrophils [4] and other cell types by blocking
activation of MEK and ERK [25]. PD 98059 (50 WM) parti-
ally reduced phosphorylation at both Ser-381 in p90-RSK
(Fig. 3C, d) and Ser-21 in GSK-3K (Fig. 3A, d) (see below).
However, the combination of wortmannin (200 nM) plus PD
98059 (50 WM) produced a striking reduction in phosphoryla-
tion of GSK-3K (Fig. 3A, e). The decreases in phosphoryla-
tion of GSK-3K were estimated by densitometry by compar-
ing the peak height of the band in lane b with that in lanes c,
d and e. Treatment of neutrophils with 200 nM wortmannin,
50 WM PD 98059 and 200 nM wortmannin plus 50 WM PD
98059 reduced the content of phosphate at Ser-21 in GSK-3K
by 11 þ 2%, 37 þ 9% and 85 þ 7% (S.D., n = 3), respectively. As
noted above, the reactivity of GSK-3L towards the phospho-
GSK-3K/L(Ser-21/9) Ab was variable. However, when signi¢-
cant amounts of GSK-3L were observed it behaved similarly
to GSK-3K in terms of its sensitivity to wortmannin and/or
PD 98059 (Fig. 3A).
In contrast to wortmannin, compound LY 294002 is a re-
versible inhibitor of PI 3-K that competes for the ATP bind-
ing site on this lipid kinase [26]. The e¡ects of LY 294002 on
the phosphorylation of GSK-3 in fMLP-stimulated neutro-
phils are presented in Fig. 4. Treatment of neutrophils with
50 WM LY 294002 or 50 WM LY 294002 plus 50 WM PD
98059 reduced the content of phosphate at Ser-21 in GSK-
3K by 30 þ 9% and 97 þ 5% (S.D., n = 3), respectively. Treat-
ment of neutrophils with 50 WM LY 294002 alone for 30 min
at 37‡C followed by stimulation of the cells with 1.0 WM
fMLP for 6.0 min reduced phosphorylation of Akt and p90-
RSK by 100 þ 0% and 18 þ 15% (S.D., n = 3), respectively
(data not shown). Thus, two structurally and mechanistically
distinct antagonists of PI 3-K were each capable of substan-
tially inhibiting the phosphorylation of GSK-3K in stimulated
neutrophils when combined with PD 98059.
Wortmannin and PD 98059 blocked phosphorylation at
Ser-381 in p90-RSK in a manner similar to that described
above for GSK-3 (Fig. 3C). Treatment of neutrophils with
200 nM wortmannin, 50 WM PD 98059 and 200 nM wort-
mannin plus 50 WM PD 98059 reduced the content of phos-
phate at Ser-381 in p90-RSK by 0%, 46 þ 2% and 63 þ 3%
(S.D. or range, n = 2^3), respectively. The concentrations of
inhibitors and conditions used in these studies did not a¡ect
cell viability, as measured by the exclusion of trypan blue or
by the release of lactate dehydrogenase from the cells (data
not shown [4,27]).
Fig. 2. Time course for the phosphorylation of GSK-3 (A), Akt (B)
and p90-RSK (C) in stimulated neutrophils. Neutrophils were stimu-
lated with 1.0 WM fMLP for the time points indicated and phos-
phorylation of GSK-3, Akt and p90-RSK was monitored by West-
ern blotting with phosphospeci¢c antibodies. The amounts of
phosphorylation of these kinases in unstimulated neutrophils at 1.0
min and 10.0 min are also shown (lanes a and f). A: The antibody
utilized recognized GSK-3K (arrow) and GSK-3L (closed arrow-
head) only when these isoforms were phosphorylated on Ser-21 and
Ser-9, respectively. B: The antibody utilized recognized Akt (open
arrowhead) only when this kinase was phosphorylated on Thr-308.
C: The antibody utilized recognized p90-RSK (broken arrow) only
when this kinase was phosphorylated on Ser-381. Conditions for
cell stimulation and Western blotting are referenced in Section 2.
Fig. 3. E¡ects of di¡erent antagonists on the phosphorylation of
GSK-3 (A), Akt (B) and p90-RSK (C) in stimulated neutrophils.
Cells were treated with the inhibitors for 30 min at 37‡C and then
stimulated with 1.0 WM fMLP for 6.0 min. Lane a is for unstimulat-
ed cells. Lane b is for stimulated cells. Lanes c^e are for stimulated
cells treated with: (c1 and c2; two di¡erent samples) 200 nM wort-
mannin; (d) 50 WM PD 98059 and (e) 50 WM PD 98059 plus 200
nM wortmannin. Site-speci¢c phosphorylation of GSK-3, Akt and
p90-RSK was monitored with the phosphospeci¢c antibodies de-
scribed in the legend to Fig. 2. Conditions for cell stimulation and
Western blotting are referenced in Section 2.
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3.4. E¡ects of wortmannin and PD 98059 on the activation of
p90-RSK-2
Studies were undertaken to determine if p90-RSK-2 from
stimulated neutrophils exhibited enhanced activity towards
the Ser-21/9 sites in GSK-3K/L and if so whether this activa-
tion was reduced by PD 98059 and/or wortmannin (Fig. 5).
p90-RSK-2 was immunoprecipitated from neutrophil lysates,
assayed with a fusion protein containing the Ser-21/9 site in
GSK-3K/L and phosphorylation of this substrate was moni-
tored with the phospho-GSK-3K/L(Ser-21/9) Ab. p90-RSK-2
from fMLP-stimulated neutrophils exhibited substantial activ-
ity with this substrate. In contrast, little activity was observed
with immunoprecipitates from unstimulated cells or if non-
immune serum was used in place of the RSK-2(C-19) Ab
(Fig. 5A).
The amounts of activity for p90-RSK-2 in the immune
complexes were markedly reduced if the cells were treated
with PD 98059 (50 WM) for 15 min before stimulation with
fMLP (Fig. 5B, c). In contrast, wortmannin (200 nM) alone
did not block activation of p90-RSK-2 (Fig. 5B, d) and the
combination of wortmannin (200 nM) plus PD 98059 (50 WM)
was only slightly more e¡ective than PD 98059 alone (Fig. 5B,
e). Treatment of neutrophils with PD 98059 (50 WM), wort-
mannin (200 nM) or PD 98059 (50 WM) plus wortmannin (200
nM) reduced the amount of phosphate in the fusion protein
by 84 þ 13%, 8 þ 11% and 87 þ 8% (S.D., n = 3), respectively.
These data demonstrate that the activity of p90-RSK-2 to-
wards the Ser-21/9 site in GSK-3K/L is markedly increased
in stimulated neutrophils and that this increase is due largely
to the MEK/ERK pathway and not to PDK-1 or Akt.
4. Discussion
In this communication we report that GSK-3K undergoes
rapid phosphorylation on Ser-21 in stimulated neutrophils. A
variable amount of phosphorylation of GSK-3L on Ser-9 was
also observed. Further, we provide evidence that these phos-
phorylation events may be catalyzed by both p90-RSK-2 and
Akt in fMLP-stimulated neutrophils. In particular, antago-
nists which block activation of p90-RSK-2 and Akt inhibited
phosphorylation of GSK-3K in a synergistic manner (Figs. 3
and 4). In addition, the progress curve for phosphorylation/
activation of Akt was consistent with this kinase being located
upstream of GSK-3 whereas that for p90-RSK-2 was consis-
tent with this kinase operating either upstream or parallel to
GSK-3 (Fig. 2) [4]. As noted above, p90-RSK-2 and Akt
Fig. 4. E¡ects of LY 294002 and PD 98059 on the phosphorylation
of GSK-3 in stimulated neutrophils. Cells were treated with the in-
hibitors for 30 min at 37‡C and then stimulated with 1.0 WM fMLP
for 6.0 min. Lane a is for unstimulated cells. Lane b is for stimu-
lated cells. Lanes c^e are for stimulated cells treated with: (c) 50
WM LY 294002, (d) 50 WM PD 98059 and (e) 50 WM LY 294002
plus 50 WM PD 98059. Site-speci¢c phosphorylation of GSK-3 was
monitored with the phospho-GSK-3K/L(Ser-21/9) Ab. Conditions
for cell stimulation and Western blotting are referenced in Section
2.
Fig. 5. Ability of p90-RSK-2 from stimulated neutrophils to cata-
lyze phosphorylation of the Ser-21/9 site in a GSK-3 fusion protein.
E¡ects of PD 98059 and wortmannin on activation of p90-RSK-2.
A: p90-RSK was immunoprecipitated from neutrophil lysates (lanes
a, b and d) and assayed for its ability to catalyze phosphorylation
of a GSK-3 fusion protein. Lane c is for neutrophil lysates treated
with non-immune serum (C-IgG) in place of the p90-RSK-2(C-19)
Ab. Cells were treated for 6.0 min with 0.25% (v/v) dimethyl sulfox-
ide (lane a; unstimulated neutrophils) or 1.0 WM fMLP (lanes b^d)
before preparing the lysates. B: Neutrophils were treated with di¡er-
ent inhibitors for 30 min at 37‡C, stimulated with 1.0 WM fMLP for
6.0 min and then lysed. p90-RSK-2 was immunoprecipitated from
the lysates and assayed with the GSK-3 fusion protein as the sub-
strate. Lane a is for unstimulated cells. Lane b is for stimulated
cells. Lanes c^e are for stimulated cells treated with: (c) 50 WM PD
98059, (d) 200 nM wortmannin and (e) 50 WM PD 98059 plus 200
nM wortmannin. Conditions for cell stimulation, immunoprecipita-
tion and assaying kinase activity in immune complexes are de-
scribed/referenced in Section 2.
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catalyze the phosphorylation of GSK-3K on Ser-21 in vitro
[13,14].
PD 98059 and wortmannin were recently shown to have the
most impressive selectivity when a variety of inhibitors were
compared against a large panel of protein kinases [23]. How-
ever, it should be emphasized that these antagonists block
activation of Akt and p90-RSK indirectly, through inhibition
of upstream components (e.g. [17,25]). Thus, the possibility
exists that these antagonists may also be a¡ecting unknown
kinases that are also active against GSK-3. It is not possible
to employ the techniques of molecular biology to directly
investigate the involvement of p90-RSK-2 and Akt in the
phosphorylation/inactivation of GSK-3 in primary neutro-
phils because these cells are short-lived. Immunohistochemical
studies may be of value here to show that these kinases are co-
localized at the appropriate time points after cell stimulation.
Compound PD 98059 and wortmannin also synergistically
inhibited phosphorylation of p90-RSK on Ser-381 in stimu-
lated neutrophils (Fig. 3C, e). However, phosphorylation at
this site does not appear to be closely associated with the
activity of p90-RSK. In particular, PD 98059 alone blocked
activation of p90-RSK-2 by 84 þ 13% (Fig. 5B, c) but inhib-
ited phosphorylation at Ser-381 by only 46 þ 2% (Fig. 3C, d).
Thus, it is unlikely that the synergistic inhibition of GSK-3
phosphorylation by PD 98059 and wortmannin can be ex-
plained simply by the e¡ects of these compounds on p90-
RSK-2 alone.
p90-RSK-2 is a highly unusual kinase in that it contains
two distinct active sites/protein kinase domains that reside in
the N-terminal and C-terminal regions of the protein [5]. The
N-terminal kinase domain (NTD) catalyzes the phosphoryla-
tion of exogenous substrates whereas the C-terminal domain
(CTD) is required for complete activation of the NTD [5,6].
The mechanism of activation of p90-RSK-2 is complex and
involves phosphorylation on Ser-381 and several other resi-
dues [6]. Phosphorylation at Ser-381 can be catalyzed by the
CTD of the kinase itself but only after activation of this
domain by an ERK- or PDK-1-catalyzed phosphorylation
event [6,7]. The ability of PD 98059 and wortmannin to syn-
ergistically inhibit phosphorylation on Ser-381 suggests that
both of these reactions for activating the CTD may be oper-
ating in fMLP-stimulated neutrophils and that products of PI
3-K may participate in the PDK-1-dependent reaction(s).
As noted above, transfection studies indicate that GSK-3L
can trigger or enhance apoptosis in various cell types [11,12].
Whether GSK-3K or GSK-3L performs a similar function in
neutrophils is not yet known. Both p90-RSK and Akt have
substrates in addition to GSK-3 that in£uence apoptosis
[8,9,28]. In fact, either LY 294002 or PD 98059 alone can
prevent the delay in neutrophil apoptosis triggered by chemo-
attractants [2,3]. Thus, these antagonists are not likely to be
helpful in determining if GSK-3 is involved in apoptosis in
neutrophils. However, the recent availability of selective an-
tagonists of GSK-3 [29] may prove useful in addressing this
question.
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